Research Site

Takarazuka-shi 665-0873

1 studies enrolling now · 9 studies all time

What they study most

Asthma, Atherothrombosis, Carcinoma, Non-Small Cell Lung, Cardiovascular Death, Chronic Kidney Disease, Heart Failure With Preserved Ejection Fraction (HFpEF), Heart Failure With Reduced Ejection Fraction (HFrEF), Hyperkalemia, IBD, Myocardial Infarction, Renal Insufficiency, Chronic, Stroke

Studies at this site

• A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer — Recruiting now
• Study to Assess PT010 in Adult and Adolescent Participants With Inadequately Controlled Asthma (KALOS) — Completed
• Placebo-Controlled Study of Brazikumab in Participants With Moderately to Severely Active Ulcerative Colitis — Stopped early
• A Study to Evaluate the Effect of Sodium Zirconium Cyclosilicate on Chronic Kidney Disease (CKD) Progression in Participants With CKD and Hyperkalaemia or at Risk of Hyperkalaemia — Stopped early
• Zibotentan and Dapagliflozin for the Treatment of CKD (ZENITH-CKD Trial) — Completed
• DETERMINE-preserved - Dapagliflozin Effect on Exercise Capacity Using a 6-minute Walk Test in Patients With Heart Failure With Preserved Ejection Fraction — Completed
• A Study to Evaluate the Effect of Dapagliflozin on Renal Outcomes and Cardiovascular Mortality in Patients With Chronic Kidney Disease — Completed
• DETERMINE-reduced - Dapagliflozin Effect on Exercise Capacity Using a 6-minute Walk Test in Patients With Heart Failure With Reduced Ejection Fraction — Completed
• Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin — Completed